Could Medtronic’s Kanghui Purchase Set Course For US Entry?
Executive Summary
Last month Medtronic agreed to pay close to $800 million for Chinese orthopedics implant maker China Kanghui Holdings. To be sure, the purchase of Kanghui secures Medtronic’s footing in China, one of the fastest growing health care economies in the world. In addition, it likely will help Medtronic close in on its goal of bringing in 20% of its revenue from emerging markets.
You may also be interested in...
Extremities, Emerging Markets Continue To Top Ortho M&As
With hip and knee joint markets still registering slow to modest growth, orthopedic companies looking to add bulk to their bottom line through mergers and acquisitions have pursued two distinct directions – the extremities and emerging markets.
Total Ankle Replacement Sparks New Race
Orthopedic companies now target the so-called extremities as an area of capable of producing double-digit growth in sales. To be sure, the markets are considerably smaller than hips or knees, but multinational leaders can’t ignore untapped potential when their core markets are stagnant, and a new front is forming in the battle for foot and ankle supremacy around an old but still underutilized device – total ankle replacement implants.
Extremities, Emerging Markets Continue To Top M&A Ortho Interest
With hip and knee joint markets still registering slow to modest growth, orthopedic companies looking to add bulk to their bottom line through mergers and acquisitions have pursued two distinct directions – the extremities and emerging markets.